Tscan therapeutics reports fourth quarter and full year 2024 financial results and provides business update

Presented updated data from ongoing alloha™ phase 1 heme trial at the 66 th ash annual meeting and exposition ind application cleared for seventh tcr in plexi-t™ phase 1 solid tumor program; tsc-202-a0201 targeting mage-a4 on hla-a*02:01 closed $30 million registered direct offering at 37% premium with long-standing, supportive shareholder cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 waltham, mass., march 05, 2025 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biotechnology company focused on the development of t cell receptor (tcr)-engineered t cell (tcr-t) therapies for the treatment of patients with cancer, today reported financial results for the three months and full year ended december 31, 2024, and provided a business update.
TCRX Ratings Summary
TCRX Quant Ranking